On January 27, 2012, Amylin Pharmaceuticals, Inc. ("Amylin") and Alkermes plc ("Alkermes") announced that the U.S. Food and Drug Administration ("FDA") has approved BYDUREON™ (exenatide extended-release for injectable suspension) - the first once-weekly treatment for type 2 diabetes. A copy of the press release is attached hereto as Exhibit 99.1. This information, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

(d) Exhibits.

Exhibit
No.                                     Description
99.1      Press release issued by Amylin and Alkermes dated January 27, 2012,
          announcing the approval of BYDUREON by the FDA.